Talphera at H.C. Wainwright conference: nafamostat path gains traction

Talphera (TLPH) updated investors on its nafamostat mesylate clinical trial at the H.C. Wainwright conference. The NEPHRO study is 75% enrolled, with topline data expected in early 2025 and a potential U.S. launch in late 2025. The FDA reduced the study size to 70 patients, maintaining 90% statistical power. New guidelines recommend nafamostat, and the company sees a larger U.S. market opportunity. The stock has gained 56% over six months, with analysts setting price targets between $3 and $3.50

Original reporting
Published Sep 14, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 5:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$TLPH
Bullish
high confidence
Mentioned
$TLPH
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$TLPHBullishMed
01

Why it matters

The disclosed milestones reduce clinical uncertainty and set a clear path to FDA filing, likely driving short‑term stock momentum.

02

Market read

Clinical progress and breakthrough designation create a near‑term catalyst for a micro‑cap biotech, with broader implications for renal‑therapy markets.

03

What to watch

Potential reimbursement challenges and competition from citrate/heparin protocols.

Relevance 8/10Novelty 8/10Timing: post‑conference Sep 14

Background

Talphera presented at the H.C. Wainwright conference, highlighting clinical and regulatory progress for its lead product nafamostat mesylate in CRRT anticoagulation.

Company-level read

Ticker impact

$TLPHBullishHigh confidence
Context

Talphera disclosed that its NEPHRO pivotal study is 75% enrolled, enrollment will finish by end‑2024, and a PMA filing is expected within three months after data readout.

Expected impact

Potential upside as investors price in earlier launch and higher market opportunity.

Evidence & confidence

Enrollment milestones and reduced sample size improve statistical power; breakthrough designation accelerates review, creating a clear catalyst.

Market effects

Strengthens outlook for CRRT anticoagulation market and may benefit related renal‑therapy equipment suppliers.

U.S. renal‑replacement therapy market sees expanded opportunity.

Guideline endorsement could spur interest in Asian markets where the drug is already available.

Counterpoint

If enrollment delays or data quality issues arise, the de‑risk narrative could reverse.

Key entities

  • Talphera

    Biotech developing nafamostat for CRRT anticoagulation.

  • FDA

    U.S. agency reviewing the NEPHRO pivotal study.

Related articles

$TLPHMed

Talphera (TLPH) Q3 2026 Earnings Call Transcript

Talphera (TLPH) reported Q3 2026 earnings, seeking FDA approval to conclude Niyad enrollment early due to 80% statistical power. They increased peak U.S. sales estimate to over $200M. Cash balance was $14.2M, with $16M in potential financing. Operating expenses rose to $3.8M from $3.3M YoY. Enrollment challenges were discussed, with no clear cause identified.

$TLPHMed

What Talphera (TLPH) Said on Its Q3 Earnings Call

Talphera (TLPH) discussed Q3 earnings, highlighting FDA submission details, increased peak-sales estimates, and cash position. The company expects $14.2M in cash and $16M in conditional financing to support operations through 2027. Expenses rose to $3.8M due to Niyad development and pre-launch activities. Talphera plans an investor event in Q1 2027 to discuss opportunities.

$TLPHMed

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a posi

$TSLAMedAI 8/10

Tesla Pours $3.3 Billion Into Berlin Cybercab Plant as Waymo Pulls Robotaxis Off Freeways — BigGo Finance

Tesla (TSLA) plans to invest $3.3 billion in its Berlin Gigafactory to produce 1 million Cybercab robotaxis annually. The company expanded its robotaxi service in Dallas and opened reservations for select customers. Meanwhile, Waymo (GOOGL) suspended freeway robotaxi services in all U.S. markets due to safety concerns. Analysts discussed potential Tesla-SpaceX (SPCX) tie-ups, and Rivian (RIVN) completed its share structure conversion.